TLR9 Activation & STAT3 Inhibition: a Bifunctional Approach to Immuno-Oncology

Time: 1:00 pm
day: Day One


  • While TLR9 continues to be a high-value target in immuno-oncology, single agent agonists of this receptor have shown limited efficacy in clinical studies.
  • This is likely due, in part, to the immunosuppression created by the tumor microenvironment, which acts as a shield protecting the tumor from the activated immune system.
  • Duet has developed a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) within the tumor microenvironment, while releasing the immunosuppressive brakes to jump-start T cell-mediated immune responses.
  • The unique mechanism-of-action of these synthetic oligonucleotides comes from simultaneously targeting two intracellular immune pathways – signal transducer and activator of transcription 3 (STAT3) and toll-like receptor 9 (TLR9).
  • The targeted inhibition of STAT3, a master immune checkpoint inhibitor, reawakens immune cells and allows for the full potential of TLR9-driven innate and adaptive immune responses.